{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T16:33:52Z","timestamp":1655397232030},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Recombinant factor VIIa (rFVIIa) may be used for rapid hemostasis in life-threatening hemorrhage. In warfarin-associated intracerebral hemorrhage (wICH), FVIIa use is controversial and may carry significant thromboembolic risks. We compared incidence of baseline thromboembolic risk factors and thromboembolism rates in wICH patients treated with additional rFVIIa to those treated with standard therapy of fresh frozen plasma (FFP) and vitamin K alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We identified 45 consecutive wICH patients treated with additional rFVIIa over 5-year period, and 34 consecutive wICH patients treated with standard therapy alone as comparison group. We compared the incidence of post-hemorrhage cardiac and extra-cardiac thromboembolic complications between two treatment groups, and used logistic regression to adjust for significant confounders such as baseline thromboembolic risk factors. We performed secondary analysis comparing the quantity of FFP transfused between two treatment cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Both rFVIIa-treated and standard therapy-treated wICH patients had a high prevalence of pre-existing thromboembolic diseases including atrial fibrillation (73% vs 68%), deep venous thrombosis (DVT) or pulmonary embolism (PE) (22% vs 18%), coronary artery disease (CAD) (38% vs 32%), and abnormal electrocardiogram (EKG) (78% vs 85%). Troponin elevation following wICH was prevalent in both groups (47% vs 41%). Clinically significant myocardial infarction (MI), defined as troponin &gt; 1.0 ng\/dL, occurred in 13% of rFVIIa-treated and 6% of standard therapy-treated patients (p=0.52). Past history of CAD (p=0.0061) and baseline abnormal EKG (p=0.02) were independently associated with clinically significant MI following wICH while rFVIIa use was not. The incidences of DVT\/PE (2% vs 9%; p=0.18) and ischemic stroke (2% vs 0%; p=0.38) were similar between two treatment groups. Recombinant FVIIa-treated patients had lower mean INR at 3 (p=0.0001) and 6 hours (p&lt;0.0001) and received fewer units of FFP transfusion (3 vs 5; p=0.003).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Pre-existing thromboembolic risk factors as well as post-hemorrhage troponin elevation are prevalent in wICH patients. Clinically significant MI occurs in up to 13% of wICH patients. rFVIIa use was not associated with increased incidence of clinically significant MI or other venous or arterial thromboembolic events in this wICH cohort.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2377-12-158","type":"journal-article","created":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T13:14:00Z","timestamp":1355577240000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case\u2013control study"],"prefix":"10.1186","volume":"12","author":[{"given":"Chou Sherry","family":"H-Y","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Xuemei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konigsberg Rachael","family":"G","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bresette Linda","family":"M","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henderson Galen","family":"V","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorond Farzaneh","family":"A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feske Steven","family":"K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,15]]},"reference":[{"key":"705_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","volume":"26","author":"RG Hart","year":"1995","unstructured":"Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995, 26: 1471-1477. 10.1161\/01.STR.26.8.1471.","journal-title":"Stroke"},{"key":"705_CR2","doi-asserted-by":"publisher","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008, 133: 257S-298S. 10.1378\/chest.08-0674.","journal-title":"Chest"},{"key":"705_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0025-6196(11)60970-1","volume":"82","author":"MI Aguilar","year":"2007","unstructured":"Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, et al: Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007, 82: 82-92.","journal-title":"Mayo Clin Proc"},{"key":"705_CR4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/01.STR.0000221786.81354.d6","volume":"37","author":"HB Huttner","year":"2006","unstructured":"Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, et al: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006, 37: 1465-1470. 10.1161\/01.STR.0000221786.81354.d6.","journal-title":"Stroke"},{"key":"705_CR5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","volume":"77","author":"M Makris","year":"1997","unstructured":"Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF: Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997, 77: 477-480.","journal-title":"Thromb Haemost"},{"key":"705_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/01.STR.23.7.972","volume":"23","author":"K Fredriksson","year":"1992","unstructured":"Fredriksson K, Norrving B, Stromblad LG: Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992, 23: 972-977. 10.1161\/01.STR.23.7.972.","journal-title":"Stroke"},{"key":"705_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/01.STR.0000195047.21562.23","volume":"37","author":"JN Goldstein","year":"2006","unstructured":"Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J: Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006, 37: 151-155.","journal-title":"Stroke"},{"key":"705_CR8","doi-asserted-by":"publisher","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004, 126: 204S-233S. 10.1378\/chest.126.3_suppl.204S.","journal-title":"Chest"},{"key":"705_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2008.05.001","volume":"23","author":"R Appelboam","year":"2009","unstructured":"Appelboam R, Thomas EO: Warfarin and intracranial haemorrhage. Blood Rev. 2009, 23: 1-9. 10.1016\/j.blre.2008.05.001.","journal-title":"Blood Rev"},{"key":"705_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/01.STR.30.4.905","volume":"30","author":"JP Broderick","year":"1999","unstructured":"Broderick JP, Adams HP, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, Mayberg M, Tilley B, et al: Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the stroke council. American heart association. Stroke. 1999, 30: 905-915. 10.1161\/01.STR.30.4.905.","journal-title":"Stroke"},{"key":"705_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.164.8.880","volume":"164","author":"J Rosand","year":"2004","unstructured":"Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004, 164: 880-884. 10.1001\/archinte.164.8.880.","journal-title":"Arch Intern Med"},{"key":"705_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.clineuro.2007.10.019","volume":"110","author":"M Felfernig","year":"2008","unstructured":"Felfernig M, Huepfl M: Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients. Clin Neurol Neurosurg. 2008, 110: 227-232. 10.1016\/j.clineuro.2007.10.019.","journal-title":"Clin Neurol Neurosurg"},{"key":"705_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1212\/01.wnl.0000238104.75563.2f","volume":"67","author":"SB Lee","year":"2006","unstructured":"Lee SB, Manno EM, Layton KF, Wijdicks EF: Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006, 67: 1272-1274. 10.1212\/01.wnl.0000238104.75563.2f.","journal-title":"Neurology"},{"key":"705_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","volume":"358","author":"SA Mayer","year":"2008","unstructured":"Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008, 358: 2127-2137. 10.1056\/NEJMoa0707534.","journal-title":"N Engl J Med"},{"key":"705_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1212\/01.wnl.0000239154.51331.c4","volume":"67","author":"RM Sugg","year":"2006","unstructured":"Sugg RM, Gonzales NR, Matherne DE, Ribo M, Shaltoni HM, Baraniuk S, Noser EA, Grotta JC: Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology. 2006, 67: 1053-1055. 10.1212\/01.wnl.0000239154.51331.c4.","journal-title":"Neurology"},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.amjcard.2005.07.097","volume":"96","author":"E Skaf","year":"2005","unstructured":"Skaf E, Stein PD, Beemath A, Sanchez J, Bustamante MA, Olson RE: Venous thromboembolism in patients with ischemic and hemorrhagic stroke. Am J Cardiol. 2005, 96: 1731-1733. 10.1016\/j.amjcard.2005.07.097.","journal-title":"Am J Cardiol"},{"key":"705_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12028-008-9134-3","volume":"10","author":"JN Goldstein","year":"2009","unstructured":"Goldstein JN, Fazen LE, Wendell L, Chang Y, Rost NS, Snider R, Schwab K, Chanderraj R, Kabrhel C, Kinnecom C, et al: Risk of thromboembolism following acute intracerebral hemorrhage. Neurocrit Care. 2009, 10: 28-34. 10.1007\/s12028-008-9134-3.","journal-title":"Neurocrit Care"},{"key":"705_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/STROKEAHA.109.561712","volume":"41","author":"MN Diringer","year":"2010","unstructured":"Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP: Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the factor seven for acute hemorrhagic stroke (FAST) trial. Stroke. 2010, 41: 48-53. 10.1161\/STROKEAHA.109.561712.","journal-title":"Stroke"},{"key":"705_CR19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1161\/STROKEAHA.110.581538","volume":"41","author":"MT Robinson","year":"2010","unstructured":"Robinson MT, Rabinstein AA, Meschia JF, Freeman WD: Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke. 2010, 41: 1459-1463. 10.1161\/STROKEAHA.110.581538.","journal-title":"Stroke"},{"key":"705_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00001721-200307000-00007","volume":"14","author":"B Sorensen","year":"2003","unstructured":"Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J: Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003, 14: 469-477. 10.1097\/00001721-200307000-00007.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"705_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-137-11-200212030-00009","volume":"137","author":"RA Deveras","year":"2002","unstructured":"Deveras RA, Kessler CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002, 137: 884-888.","journal-title":"Ann Intern Med"},{"key":"705_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1046\/j.1365-2141.2002.03437.x","volume":"117","author":"GT Gerotziafas","year":"2002","unstructured":"Gerotziafas GT, Zervas K, Arzoglou P, Karavaggeli E, Parashou S, Van Dreden P, Christakis J, Samama MM: On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation. Br J Haematol. 2002, 117: 705-708. 10.1046\/j.1365-2141.2002.03437.x.","journal-title":"Br J Haematol"},{"key":"705_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jclinane.2007.12.012","volume":"20","author":"C Ilyas","year":"2008","unstructured":"Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR: Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 2008, 20: 276-279. 10.1016\/j.jclinane.2007.12.012.","journal-title":"J Clin Anesth"},{"key":"705_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1182\/blood-2009-11-253492","volume":"116","author":"BE Skolnick","year":"2010","unstructured":"Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME: Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010, 116: 693-701. 10.1182\/blood-2009-11-253492.","journal-title":"Blood"},{"key":"705_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1365-2257.2005.00713.x","volume":"27","author":"S Conti","year":"2005","unstructured":"Conti S, La Torre D, Gambelunghe G, Ciorba E, Iorio A: Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. Clin Lab Haematol. 2005, 27: 283-285. 10.1111\/j.1365-2257.2005.00713.x.","journal-title":"Clin Lab Haematol"},{"key":"705_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.4065\/79.12.1495","volume":"79","author":"WD Freeman","year":"2004","unstructured":"Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG, Czervionke LF, Meschia JF: Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004, 79: 1495-1500. 10.4065\/79.12.1495.","journal-title":"Mayo Clin Proc"},{"key":"705_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/TA.0b013e3181650fc7","volume":"64","author":"DM Stein","year":"2008","unstructured":"Stein DM, Dutton RP, Kramer ME, Handley C, Scalea TM: Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma. 2008, 64: 620-627. 10.1097\/TA.0b013e3181650fc7. discussion 627\u2013628","journal-title":"J Trauma"},{"key":"705_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1385\/NCC:2:3:263","volume":"2","author":"DL Brody","year":"2005","unstructured":"Brody DL, Aiyagari V, Shackleford AM, Diringer MN: Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005, 2: 263-267. 10.1385\/NCC:2:3:263.","journal-title":"Neurocrit Care"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-12-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-12-158\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-12-158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-12-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:25:25Z","timestamp":1630531525000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-12-158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-12-158","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"13 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"158"}}